Angiopoietin and Adverse Outcomes in Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
Cardiac surgery and cardiopulmonary bypass can lead to systemic organ failure trough excess inflammation and endothelial injury. The angiopoietin family represented by angiopoietin 1 and 2 can reflect endothelial injury by a decrease in angiopoietin 1 and an increase in angiopoietin 2. The investigators hypothesized that angiopoietin dysregulation could reflect organ failure related to cardiac surgery. The purpose of this project is to assess the association between angiopoietin dysregulation and adverse outcomes on cardiac surgery.

Official Title
-----------------
Angiopoietin Dysregulation to Predict Adverse Outcomes in Cardiac Surgery: the Prospective

Conditions
-----------------
Cardiac Surgery, Acute Kidney Injury

Intervention / Treatment
-----------------
* Other: blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patient scheduled for cardiac surgery under cardiopulmonary bypass Exclusion Criteria: patient less than 18 years old, redo surgery, urgent surgery, endocarditis, aortic root repair surgery aortic dissection heart beating surgery, heart transplantation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: cardiac surgery<br> | Other: blood sample<br>* 5 ml blood sample will be withdrawn at the surgery start and at the surgery end<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between abnormal angiopoietin 1 concentration (ng/ml) and number of major cardiovascular event | major cardiovascular event are myocardial infraction, stroke, acute kidney injury, cardiovascular death | 28 days | 
| correlation between occurence of abnormal angiopoietin 2 concentration (ng/ml) and occurence of major cardiovascular event | major cardiovascular event are myocardial infraction, stroke, acute kidney injury, cardiovascular death | 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between abnormal angiopoietin 1 concentration (ng/ml) and number of postoperative pulmonary complications |  | 28 days | 
| Correlation between abnormal angiopoietin 2 concentration (ng/ml) and number of postoperative pulmonary complications |  | 28 days | 
| Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality at 3 months |  | 3 months | 
| Correlation between abnormal angiopoietin 2 concentration (ng/ml) and mortality at 3 months |  | 3 months | 
| Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality at 6 months |  | 6 months | 
| Correlation between occurence of abnormal angiopoietin 2 concentration (ng/ml) and mortality at 6 months |  | 6 months | 
| Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality rate at 12 months |  | 12 months | 
| Correlation between abnormal angiopoietin 2 concentration (ng/ml) and mortality rate at 12 months |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
angiopoietin, endothelial injury, MACCE